fesoterodine fesoterodine fesoterodine (inn, used as the fumarate under the brand name toviaz) is an antimuscarinic drug developed by schwarz pharma ag to treat overactive bladder syndrome (oab). it was approved by the european medicines agency in april 2007, the us food and drug administration on october 31, 2008 and health canada on february 9, 2012. fesoterodineclinical datatrade namestoviazahfs/drugs.commonographmedlineplusa609021license data eu ema: by inn us dailymed: fesoterodine us fda: fesoterodine routes ofadministrationby mouthatc codeg04bd11 (who) legal statuslegal status ca: ℞-only us: ℞-only eu: rx-only pharmacokinetic databioavailability52% (active metabolite)protein binding50% (active metabolite)metabolismliver (cyp2d6- and 3a4-mediated)elimination half-life7–8 hours (active metabolite)excretionkidney (70%) and fecal (7%)identifiers iupac name -4-(hydroxymethyl)phenyl] 2-methylpropanoate cas number286930-02-7 npubchem cid6918558iuphar/bps7473drugbankdb06702 ychemspider5293755 yunii621g617227keggd07226 ychemblchembl1201764 ncomptox dashboard (epa)dtxsid80182853 echa infocard100.184.854 chemical and physical dataformulac26h37no3molar mass411.586 g·mol−13d model (jsmol)interactive image smiles o=c(oc1ccc(cc1(c2ccccc2)ccn(c(c)c)c(c)c)co)c(c)c inchi inchi=1s/c26h37no3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28h,14-15,17h2,1-6h3/t23-/m1/s1 ykey:dccsdbarqiptgu-hszrjfapsa-n y ny (what is this?) (verify) fesoterodine is a prodrug. it is broken down into its active metabolite, desfesoterodine, by plasma esterases. efficacy fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists. its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder. a japanese study from 2017, showed that urgency and urge incontinence are improved after 3 days administration of the drug, with full efficacy able to be judged after 7 days administration. overactive bladder was found to be resolved in 88% of patients after seven days usage.